Navigation Links
OncoSec Medical to Present at Industry and Investor Conferences
Date:8/24/2011

SAN DIEGO, Aug. 24, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, announced today that the company will be presenting a corporate overview at an upcoming investor conference and attending an industry event for medical devices.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO) BIOCOM Device Fest 2011Costa Mesa, CA, August 25Westin South Coast PlazaSouthern California Investor ConferenceNewport Beach, CA, August 29The Island HotelOncoSec Medical PresentationMichael Cross, Ph.D., Chief Business OfficerAbout OncoSec Medical Inc.OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec's clinical programs include three Phase II clinical trials. More information is available at www.oncosec.com.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
2. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
3. OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
4. OncoSec Medical Closes $1.1M Financing
5. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
6. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
7. OncoSec Medical Appoints Engineering Leader
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. Globus Medical Raises $110 Million in Series E Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... and TEL AVIV, Israel , March 28, 2017 ... Israel . This new business entity, Emosis Ltd, ... dedicated to research and development of novel assays complementing the mother ... when relevant, locally support commercialization and sales development of Emosis kits. ... This strategic move ...
(Date:3/28/2017)... 2017  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a ... and other unmet medical needs, announced today two ... Research annual meeting.  The first poster to be ... of ENMD-2076 in Combination with Anti-PD1 in Syngeneic ... be presented on April 4 is entitled " ...
(Date:3/28/2017)... SAN FRANCISCO , March 28, 2017 ... is expected to reach USD 8.0 billion by 2025, ... Inc. The increasing incidence of infectious diseases and cancer ... for use in disease diagnosis over the coming years. ... the usage of autologous and allogenic stem cell therapy, ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... A minimally ... the “perfect smile.” The National Association of Dental Laboratories (NADL) is informing dentists ... be aware of when utilizing dental laboratories and technicians that create these veneers. ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Lice Treatment Center® booth ... 13-16, was a busy spot this year. Liz Solovay and Adrian Picheny, the ... outbreaks among camp communities during the upcoming 2017 camping season. “Lice infestations at ...
(Date:3/28/2017)... ... 2017 , ... Thank you to all who attended Capio Partners Winter 2017 ... was exclusive to providers and offered an opportunity to collaborate and network with healthcare ... Grand Hyatt where attendees gathered for a lively discussion on trends and issues that ...
(Date:3/27/2017)... ... ... New patients who have sleep apnea in Aurora, CO, can now ... Sleep apnea is often left untreated because patients are not familiar with common symptoms ... , Dr. Braasch seeks to raise awareness of sleep apnea in Aurora, CO, and ...
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. Justin Kolnick, Kara ... by teaching their patients about the key role this treatment plays in protecting oral ... experienced endodontist. To better serve those who need a root canal in White Plains, ...
Breaking Medicine News(10 mins):